Cell therapies often involve introduction of genetically transformed cells into a patient. Recently there has been renewed interest in non-viral gene modification for this application as an alternative to lentiviral vectors. Non-viral electroporation utilizing CRISPR-Cas9 is continuing to show improved performance and safety benefits in the area of cell-based immunotherapy. Furthermore, because electroporation is easy and rapid, it is able to transfect a large number of cells in a short time once optimum electroporation conditions are determined.
During this webinar, we will discuss the Gibco™ CTS™ Xenon™ Electroporation System, which has been developed to deliver reliably high transfection performance in volumes of 1–25 mL in a closed system with improved cell viability and recovery. The programmable interface, process flexibility, sterile single-use consumables, and available 21 CFR Part 11 compliance–compatible software upgrade- allow the system to seamlessly scale with your cell therapy process from development through clinical manufacturing. The 1 mL electroporation chamber enables efficient process development and scales directly to commercial manufacturing using the 5–25 mL cartridge. This larger volume consumable enables sterile processing, and an OPC-UA interface allows connectivity to a 21 CFR Part 11–compliant system.
- Understand how process flexibility and ability to optimize electroporation protocols can assist through the process development phase of acell therapy program
- Discuss the typical numbers of cells required for cell therapy process development and manufacturing applications
- Explore the safety, performance, and regulatory advantages of mechanical, non-viral transfection for cell therapy
Read more here: Source link